News

Under the terms of the agreement, BioWa will provide GlaxoSmithKline (GSK) with non-exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology

Approximately 21 adult patients with multiple myeloma have been enrolled in this multicenter, open-label single-arm Phase I/II study receiving milatuzumab intravenously twice weekly for four weeks. At study

EpiCept intends to use the net proceeds it receives to repay a portion of the outstanding principal of its senior secured loan with Hercules Technology Growth Capital. The

According to Proteolix, PR-047 is the first oral compound in a new class of highly specific proteasome inhibitors. PR-047 was designed by Proteolix scientists to combine the pharmacological

The ongoing Phase II study demonstrates that darinaparsin is clinically active in heavily pretreated, relapsed or refractory patients with lymphoma. Of 15 evaluable patients, four patients (27%) had

Prior to Amylin, Ms Graham served as group chairman, office of the president, for Guidant, a cardiovascular medical device manufacturer, and held a number of management positions at

This analysis of 321 patients found that, 24 months after achieving their best response, 93.8% of patients who continued therapy for more than 10 months were still alive,

Currently under development, CyDex’s new intravenous formulation of melphalan is enabled by Captisol – the company’s proprietary and patented sulfobutylether beta-cyclodextrin. Melphalan is an FDA-approved chemotherapy for multiple

The Phase I study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated subcutaneous administrations of ALX-0681. Ablynx will recruit up to 36 healthy volunteers